Logo image of APLI.CA

APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:APLI - CA03783R1073 - Common Stock

0.025 CAD
0 (0%)
Last: 12/4/2025, 7:00:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to APLI. APLI was compared to 32 industry peers in the Pharmaceuticals industry. APLI has a bad profitability rating. Also its financial health evaluation is rather negative. APLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APLI had negative earnings in the past year.
APLI had a negative operating cash flow in the past year.
In the past 5 years APLI always reported negative net income.
APLI had negative operating cash flow in 4 of the past 5 years.
APLI.CA Yearly Net Income VS EBIT VS OCF VS FCFAPLI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M -20M -25M

1.2 Ratios

APLI has a worse Return On Assets (-347.87%) than 96.88% of its industry peers.
Industry RankSector Rank
ROA -347.87%
ROE N/A
ROIC N/A
ROA(3y)-211.81%
ROA(5y)-203.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APLI.CA Yearly ROA, ROE, ROICAPLI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APLI.CA Yearly Profit, Operating, Gross MarginsAPLI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

APLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APLI remains at a similar level compared to 1 year ago.
Compared to 5 years ago, APLI has more shares outstanding
Compared to 1 year ago, APLI has an improved debt to assets ratio.
APLI.CA Yearly Shares OutstandingAPLI.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
APLI.CA Yearly Total Debt VS Total AssetsAPLI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

APLI has an Altman-Z score of -197.73. This is a bad value and indicates that APLI is not financially healthy and even has some risk of bankruptcy.
APLI has a Altman-Z score of -197.73. This is amonst the worse of the industry: APLI underperforms 96.88% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -197.73
ROIC/WACCN/A
WACC3.71%
APLI.CA Yearly LT Debt VS Equity VS FCFAPLI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M

2.3 Liquidity

APLI has a Current Ratio of 0.05. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
APLI's Current ratio of 0.05 is on the low side compared to the rest of the industry. APLI is outperformed by 96.88% of its industry peers.
APLI has a Quick Ratio of 0.05. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of APLI (0.05) is worse than 96.88% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
APLI.CA Yearly Current Assets VS Current LiabilitesAPLI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.77% over the past year.
APLI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.87%.
APLI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -12.88% yearly.
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.43%
Revenue 1Y (TTM)-87.87%
Revenue growth 3Y-58.35%
Revenue growth 5Y-12.88%
Sales Q2Q%2289.11%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APLI.CA Yearly Revenue VS EstimatesAPLI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 200K 400K 600K 800K 1M
APLI.CA Yearly EPS VS EstimatesAPLI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0 0 0 0 0

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

APLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLI.CA Price Earnings VS Forward Price EarningsAPLI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLI.CA Per share dataAPLI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

APLI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPILI THERAPEUTICS INC-CL A

TSX:APLI (12/4/2025, 7:00:00 PM)

0.025

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)02-12 2026-02-12
Inst Owners11.84%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap3.03M
Revenue(TTM)100.40K
Net Income(TTM)-2.62M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.13
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -347.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-211.81%
ROA(5y)-203.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.93%
Cap/Sales 0.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -197.73
F-Score1
WACC3.71%
ROIC/WACCN/A
Cap/Depr(3y)78.19%
Cap/Depr(5y)66.91%
Cap/Sales(3y)1.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.43%
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-87.87%
Revenue growth 3Y-58.35%
Revenue growth 5Y-12.88%
Sales Q2Q%2289.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y95.99%
OCF growth 3YN/A
OCF growth 5YN/A

APPILI THERAPEUTICS INC-CL A / APLI.CA FAQ

What is the ChartMill fundamental rating of APPILI THERAPEUTICS INC-CL A (APLI.CA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to APLI.CA.


Can you provide the valuation status for APPILI THERAPEUTICS INC-CL A?

ChartMill assigns a valuation rating of 0 / 10 to APPILI THERAPEUTICS INC-CL A (APLI.CA). This can be considered as Overvalued.


How profitable is APPILI THERAPEUTICS INC-CL A (APLI.CA) stock?

APPILI THERAPEUTICS INC-CL A (APLI.CA) has a profitability rating of 0 / 10.